- Home
- RIGL vs VKI Comparison
RIGL vs VKI Comparison
Compare RIGL & VKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- VKI
- Stock Information
- Founded
- RIGL 1996
- VKI 1993
- Country
- RIGL United States
- VKI United States
- Employees
- RIGL N/A
- VKI N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- VKI Finance Companies
- Sector
- RIGL Health Care
- VKI Finance
- Exchange
- RIGL Nasdaq
- VKI Nasdaq
- Market Cap
- RIGL 334.5M
- VKI 376.6M
- IPO Year
- RIGL 2000
- VKI N/A
- Fundamental
- Price
- RIGL $18.28
- VKI $8.41
- Analyst Decision
- RIGL Buy
- VKI
- Analyst Count
- RIGL 5
- VKI 0
- Target Price
- RIGL $36.40
- VKI N/A
- AVG Volume (30 Days)
- RIGL 205.1K
- VKI 112.8K
- Earning Date
- RIGL 05-06-2025
- VKI 01-01-0001
- Dividend Yield
- RIGL N/A
- VKI 4.52%
- EPS Growth
- RIGL N/A
- VKI N/A
- EPS
- RIGL 2.08
- VKI N/A
- Revenue
- RIGL $203,077,000.00
- VKI N/A
- Revenue This Year
- RIGL $24.45
- VKI N/A
- Revenue Next Year
- RIGL $7.23
- VKI N/A
- P/E Ratio
- RIGL $8.77
- VKI N/A
- Revenue Growth
- RIGL 70.16
- VKI N/A
- 52 Week Low
- RIGL $7.48
- VKI $7.07
- 52 Week High
- RIGL $29.82
- VKI $8.98
- Technical
- Relative Strength Index (RSI)
- RIGL 47.44
- VKI 48.78
- Support Level
- RIGL $17.65
- VKI $8.46
- Resistance Level
- RIGL $19.75
- VKI $8.55
- Average True Range (ATR)
- RIGL 1.46
- VKI 0.08
- MACD
- RIGL -0.02
- VKI 0.02
- Stochastic Oscillator
- RIGL 16.39
- VKI 45.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About VKI Invesco Advantage Municipal Income Trust II of Beneficial Interest (DE)
Invesco Advantage Municipal Income Trust II is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.